Literature DB >> 19749757

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Yasuhito Tanaka1, Nao Nishida, Masaya Sugiyama, Masayuki Kurosaki, Kentaro Matsuura, Naoya Sakamoto, Mina Nakagawa, Masaaki Korenaga, Keisuke Hino, Shuhei Hige, Yoshito Ito, Eiji Mita, Eiji Tanaka, Satoshi Mochida, Yoshikazu Murawaki, Masao Honda, Akito Sakai, Yoichi Hiasa, Shuhei Nishiguchi, Asako Koike, Isao Sakaida, Masatoshi Imamura, Kiyoaki Ito, Koji Yano, Naohiko Masaki, Fuminaka Sugauchi, Namiki Izumi, Katsushi Tokunaga, Masashi Mizokami.   

Abstract

The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients. We report a genome-wide association study (GWAS) to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population. We found two SNPs near the gene IL28B on chromosome 19 to be strongly associated with NVR (rs12980275, P = 1.93 x 10(-13), and rs8099917, 3.11 x 10(-15)). We replicated these associations in an independent cohort (combined P values, 2.84 x 10(-27) (OR = 17.7; 95% CI = 10.0-31.3) and 2.68 x 10(-32) (OR = 27.1; 95% CI = 14.6-50.3), respectively). Compared to NVR, these SNPs were also associated with SVR (rs12980275, P = 3.99 x 10(-24), and rs8099917, P = 1.11 x 10(-27)). In further fine mapping of the region, seven SNPs (rs8105790, rs11881222, rs8103142, rs28416813, rs4803219, rs8099917 and rs7248668) located in the IL28B region showed the most significant associations (P = 5.52 x 10(-28)-2.68 x 10(-32); OR = 22.3-27.1). Real-time quantitative PCR assays in peripheral blood mononuclear cells showed lower IL28B expression levels in individuals carrying the minor alleles (P = 0.015).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19749757     DOI: 10.1038/ng.449

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  23 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

3.  Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.

Authors:  Savino Bruno; Calogero Cammà; Vito Di Marco; Mariagrazia Rumi; Maria Vinci; Mario Camozzi; Chiara Rebucci; Danilo Di Bona; Massimo Colombo; Antonio Craxì; Mario U Mondelli; Giovanbattista Pinzello
Journal:  J Hepatol       Date:  2004-09       Impact factor: 25.083

4.  Appropriate data cleaning methods for genome-wide association study.

Authors:  Taku Miyagawa; Nao Nishida; Jun Ohashi; Ryosuke Kimura; Akihiro Fujimoto; Minae Kawashima; Asako Koike; Tsukasa Sasaki; Hisashi Tanii; Takeshi Otowa; Yoshio Momose; Yasuo Nakahara; Jun Gotoh; Yuji Okazaki; Shoji Tsuji; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2008-08-12       Impact factor: 3.172

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Authors:  Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Hepatol       Date:  2006-11-07       Impact factor: 25.083

7.  Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads.

Authors:  Hitomi Sezaki; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2008-10-28       Impact factor: 3.199

8.  Variant between CPT1B and CHKB associated with susceptibility to narcolepsy.

Authors:  Taku Miyagawa; Minae Kawashima; Nao Nishida; Jun Ohashi; Ryosuke Kimura; Akihiro Fujimoto; Mihoko Shimada; Shinichi Morishita; Takashi Shigeta; Ling Lin; Seung-Chul Hong; Juliette Faraco; Yoon-Kyung Shin; Jong-Hyun Jeong; Yuji Okazaki; Shoji Tsuji; Makoto Honda; Yutaka Honda; Emmanuel Mignot; Katsushi Tokunaga
Journal:  Nat Genet       Date:  2008-09-28       Impact factor: 38.330

9.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

10.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

View more
  804 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

2.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

3.  Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus.

Authors:  Michael O Baclig; Karen G Reyes; Cynthia A Mapua; Juliet Gopez-Cervantes; Filipinas F Natividad
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

Review 4.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

5.  RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus.

Authors:  Rodney P Kincaid; Victor L Lam; Rachel P Chirayil; Glenn Randall; Christopher S Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

6.  A human PSMB11 variant affects thymoproteasome processing and CD8+ T cell production.

Authors:  Izumi Ohigashi; Yuki Ohte; Kazuya Setoh; Hiroshi Nakase; Akiko Maekawa; Hiroshi Kiyonari; Yoko Hamazaki; Miho Sekai; Tetsuo Sudo; Yasuharu Tabara; Hiromi Sawai; Yosuke Omae; Rika Yuliwulandari; Yasuhito Tanaka; Masashi Mizokami; Hiroshi Inoue; Masanori Kasahara; Nagahiro Minato; Katsushi Tokunaga; Keiji Tanaka; Fumihiko Matsuda; Shigeo Murata; Yousuke Takahama
Journal:  JCI Insight       Date:  2017-05-18

7.  Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.

Authors:  Noritomo Shimada; Hidenori Toyoda; Akihito Tsubota; Tatsuya Ide; Koichi Takaguchi; Keizo Kato; Masaki Kondoh; Kazuhiro Matsuyama; Takashi Kumada; Michio Sata
Journal:  J Gastroenterol       Date:  2013-11-28       Impact factor: 7.527

Review 8.  Translating the Untranslated Region.

Authors:  Johannes Schwerk; Ram Savan
Journal:  J Immunol       Date:  2015-10-01       Impact factor: 5.422

9.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

Review 10.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.